Back to Search
Start Over
Evidence for a selective role of the delta-opioid agonist [8R-(4bS*,8aalpha,8abeta, 12bbeta)]7,10-Dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses.
- Source :
-
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2003 Dec; Vol. 307 (3), pp. 1079-89. Date of Electronic Publication: 2003 Oct 09. - Publication Year :
- 2003
-
Abstract
- The specific involvement of the delta-opioid receptor in the control of nociception was explored by investigating the pharmacological activity in vivo of a selective, orally active, and centrally penetrant delta-opioid agonist. [8R-(4bS*,8aalpha,8abeta,12bbeta)]7,10-dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) is a new pyrrolomorphinan with high affinity (Ki = 4.81 +/- 0.39 nM) for the delta-opioid receptor, full agonist activity, and binding selectivity versus the mu- and kappa-opioid receptors of 189-fold and 52-fold, respectively. Perorally administered SB-236863 was inactive in the rat tail-flick and hot-plate tests of acute pain response, but potently reversed thermal hyperalgesia in rats resulting from a carrageenan-induced inflammatory response. This activity could be blocked by the delta-opioid antagonist naltrindole (3 mg/kg s.c.), but selective mu- and kappa-opioid antagonists were ineffective. Naltrindole (1 microg i.c.v.) also blocked the activity of 10 mg/kg (p.o.) SB-235863, showing that the compound activates delta-opioid receptor sites in the central nervous system. SB-235863 was additionally effective at reversing chronic hyperalgesia in the Seltzer rat model of partial sciatic nerve ligation after peroral administration. These data show that the delta-opioid receptor plays a selective role in regulating evoked and lasting changes in nociceptive pain signaling. Classical side effects of mu- and kappa-opioid receptor activation (slowing of gastrointestinal transit and motor incoordination, respectively) were not observed after administration of 70 mg/kg (p.o.) SB-235863, nor was evoked seizure activity affected. These results suggest a selective and limited role of delta-opioid receptors in the modulation of nociception.
- Subjects :
- Animals
Binding, Competitive drug effects
Carrageenan
Cells, Cultured
Convulsants
Cyclic AMP metabolism
Electroshock
Enzymes metabolism
Gastrointestinal Transit drug effects
Genes, Reporter genetics
Hyperalgesia chemically induced
Hyperalgesia etiology
Inflammation chemically induced
Injections, Intraventricular
Luciferases genetics
Male
Morphine Derivatives metabolism
Narcotics metabolism
Pentylenetetrazole
Postural Balance drug effects
Rats
Rats, Sprague-Dawley
Receptors, Opioid, delta metabolism
Sciatic Neuropathy complications
Sciatic Neuropathy pathology
Seizures chemically induced
Seizures prevention & control
Transfection
Hyperalgesia prevention & control
Inflammation complications
Morphine Derivatives therapeutic use
Narcotics therapeutic use
Peripheral Nervous System Diseases complications
Receptors, Opioid, delta agonists
Subjects
Details
- Language :
- English
- ISSN :
- 0022-3565
- Volume :
- 307
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The Journal of pharmacology and experimental therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 14551288
- Full Text :
- https://doi.org/10.1124/jpet.103.055590